Anhui Wanbang Pharmaceutical Technology Co.,Ltd. (SHE:301520)

China · Delayed Price · Currency is CNY

44.80

-1.10 (-2.40%)

Apr 16, 2026, 4:00 PM EDT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Clinical Research Services	303.67M	243.69M	188.12M	149.73M	99.56M
Clinical Research Services Growth	24.62%	29.54%	25.64%	50.40%	-
Pharmaceutical Research Services	38.52M	60.45M	50.02M	45.94M	30.55M
Pharmaceutical Research Services Growth	-36.28%	20.86%	8.87%	50.37%	-
Other	36.90M	37.67M	22.64M	4.76M	2.99M
Other Growth	-2.04%	66.36%	375.58%	59.46%	-
Total	379.09M	341.81M	260.78M	200.44M	133.09M
Total Growth	10.91%	31.07%	30.10%	50.60%	32.42%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China	379.09M	341.81M	260.78M	211.09M	139.13M
China Growth	10.91%	31.07%	23.54%	51.72%	35.02%
Total	379.09M	341.81M	260.78M	211.09M	139.13M
Total Growth	10.91%	31.07%	23.54%	51.72%	35.02%

Source: S&P Global Market Intelligence.